Group items tagged

Community pharmacists across the UK are looking for ways to reduce operational costs and find new sources of revenue. This is a pressing issue for the sector: reversing a decade of cuts to pharmacy funding will be a mammoth task, while pharmacists have taken on new primary care responsibilities under Pharmacy First. This means that fresh sources of revenue and lower costs will overwhelmingly come from new technology and the efficiencies they can bring. As Britain's 11,500 community pharmacies assume a larger role on the frontlines of primary care, pharmacists should rapidly implement cost-effective tech solutions that provide pharmacies with a one-stop-shop to drive down costs and increase revenue. Opportunity in PGD reform New technology will be key for community pharmacists to benefit fully from reforms to PGDs. The scope of PGDs is now significantly expanding: as of June 26, pharmacy technicians are now on the list of registered healthcare professionals who can make use of PGDs. These reforms can benefit community pharmacies in several ways. For one, they will allow more pharmacy staff to administer 'frontline services' such as vaccinations - reducing costs and generating revenue. Further, the wider range of services that pharmacies can offer under Pharmacy First will make these procedures, as well as other kinds of preventative care, more accessible and convenient - increasing footfall. With international travel and tourism now growing apace, increased demand for travel vaccinations means that, according to research from Charac, the average UK community pharmacy can expect to generate £46,800 a year through travel health services.

Responding to an MP's question in the House of Commons, prime minister Rishi Sunak reiterated his deep concern for the future of UK community pharmacies, stressing their commitment to enhancing the sector with an additional £645 million in funding through the Pharmacy First initiative. At the recent Prime Minister's Questions last Wednesday, Angela Richardson, the Conservative MP for Guildford, raised the issue of rising pharmacy closures, revealing that Guildford recently lost two neighbouring pharmacies. Highlighting that empowering local pharmacies is a key part of this government's plan to cut waiting lists, she asked Sunak whether he would agree that it is vital for residents to have access to "a good, efficient, and above all, local pharmacy." In response, Sunak said: "I care deeply about the future of our community pharmacies."

A recent report published by the General Pharmaceutical Council (GPhC) has highlighted a significant increase in the number of registered pharmacists and pharmacy technicians, indicating the expanding role of these professionals in the UK healthcare system. As of May 31, 2024, the GPhC register recorded a total of 90,739 pharmacy professionals, up from 90,604 at the end of April 2024. This includes 64,415 pharmacists and 26,324 pharmacy technicians, maintaining a steady split of 71 per cent pharmacists and 29 per cent pharmacy technicians. This reflects an overall increase of four pharmacists and 131 pharmacy technicians from the previous month. The report underscores the critical role of pharmacy professionals in ensuring high-quality patient care and supporting the operational efficiency of pharmacies.

Well Pharmacy, the UK's leading independent pharmacy chain, has launched its new Online Doctor service in partnership with Expert Health Ltd. The service provides quick, convenient, and confidential access to prescription treatments for a wide range of conditions, without the need for in-person consultations. Patients can choose how they receive their prescriptions, with options for home delivery, collection at a local Well Pharmacy, or pickup from John Bell & Croydon. Andrew Caplan, Chief Retail Officer at Well Pharmacy, said: "Our Online Doctor service is a step forward in making healthcare more accessible and tailored to modern lifestyles. "It provides an efficient, secure, and discreet way for patients to access the treatments they need, all backed by the expertise and trustworthiness of Well Pharmacy." The launch of this service reinforces Well Pharmacy's ongoing commitment to improving access to healthcare and meeting the evolving needs of patients. By removing traditional barriers to obtaining prescriptions, Well aims to empower patients to take control of their health safely and efficiently. Andy Sloman, CEO of Expert Health Ltd, commented: "Digital healthcare becomes so much more powerful when combined with the expertise and human touch of healthcare professionals."

Over the last few years pharmacy and the role of pharmacy teams has changed dramatically. The introduction of technology and the integration of artificial intelligence (AI) within systems that provide healthcare and support to pharmacies holds great promise; for improving access to health, supporting patient outcomes, and optimising operational efficiency. Currently, the potential use of AI could span the whole of the medicines value chain, from AI-driven drug discovery to personalised medicines and automated dispensing systems. However, the rapid advancement of AI technology does raise several ethical concerns. This article will explore these concerns and how they can be addressed. In previous articles, I have discussed what underpins artificially intelligent machines and the importance of data. Datasets are the foundation on which AI algorithms learn and generate conclusions. The first step to understanding the potential ethical implications of AI across the pharmacy sector is to understand the data that is held within these foundational datasets. Patient privacy and data security AI systems in and outside of the pharmacy sector, which support patient care, rely heavily on vast amounts of medical data (patient medical records, PMR data, etc). However, the collection, storage, and use of such sensitive data can possibly bring significant privacy concerns. GDPR compliance is essential within the UK and ethical questions arise around data ownership, patient consent, and the possibility of data and cybersecurity breaches. As frontline healthcare professionals, we need to be able to support our patients when questions are asked about their data. For example, how can patients be sure their data is used only for its intended purposes? Is anonymised data truly safe from de-identification techniques that could expose private information?

A new report has suggested that adopting hub and spoke dispensing model could be a realistic and affordable option for many pharmacies across the UK, not just a select few. The report released by Centred Solutions highlighted several evidence-based benefits of this model, including a return on investment (ROI) within two years for an average pharmacy, debunking the skepticism that has long surrounded the model. Analysis by the software and technology company found that the ROI, from setting up a hub and all operational costs (excluding transport), can be achieved through either re-directing time saved into delivering services, improving resource efficiencies, or a combination of both. One of the key findings is the 81 per cent reduction in payroll costs per item-from 99p in a pharmacy to just 19p in a hub. The report also revealed that by shifting to a hub and spoke model, pharmacies could offload 50 per cent of total dispensing volumes (70-80 per cent of repeat dispensing) from their branches, creating much-needed capacity. The report also projected an average stock reduction of 50 per cent in the first year for pharmacy branches moving to this model of dispensing.

Omnicell UK & Ireland, a leading provider of pharmacy and nursing care automation solutions, has announced a strategic partnership with Gollmann to integrate the German manufacturers' advanced robotic storage and dispensing technology into its retail and central pharmacy solutions portfolio. This collaboration aims to address the increasing pressure on community pharmacies and hospitals to enhance patient safety and meet strict regulatory standards while improving operational efficiency. By combining Omnicell's extensive expertise with Gollmann's innovative technology, the partnership intends to streamline real-time medication dispensing and loading activities, thereby delivering improved workflows and outcomes. Nnamdi Njoku, executive vice president and chief operating officer of Omnicell, highlighted the company's commitment to providing software and automation solutions to ensure "safe, efficient medication and supply management across the healthcare continuum." "Through strategic relationships with technology leaders like Gollmann, and others announced earlier this month with TrackTraceRX, LSPedia, and Follett, we are growing our solutions portfolio as we seek to meet the evolving needs of our global customers, while being focused on driving greater efficiency and working to improve patient safety across hospital and retail settings," he said.

The General Pharmaceutical Council (GPhC) has announced plans to update the pharmacy inspection process by adopting a more targeted and flexible approach. The GPhC inspects registered pharmacies in Great Britain to ensure they meet required standards, assuring patients and the public of safe, effective care. During its Council meeting today (12), the pharmacy regulator outlined plans to improve its inspection approach, including the introduction of shorter, more focused inspections alongside the existing full inspections, to increase efficiency and enable more inspection activity. Inspectors can switch to a full inspection if they believe it is necessary or beneficial. Pharmacies being inspected for the first time will automatically undergo a full inspection. In addition to focused and full inspections, other types, such as re-inspections, intelligence-led inspections, and themed inspections, will also continue.

The Royal Pharmaceutical Society (RPS) has published a new policy outlining how artificial intelligence (AI) can be used to support pharmacy practice and improve patient care. The content has been developed in consultation with RPS members, Expert Advisory Group members, Board members, multi-professional experts in digital technology and AI, and external stakeholders including the General Pharmaceutical Council (GPhC). The policy highlights the opportunities, challenges and potential applications of AI within pharmacy now and in the future. RPS President, Professor Claire Anderson, acknowledges that AI technologies have the potential to transform pharmacy practice, noting that "there are some great examples where it's already in use." "We must optimise the opportunities that these advancing technologies can bring to enhance patient access to care, improve patient experience, support clinical decision making and improve the safety and efficiency of the medicines supply chain. "Our policy provides a framework to ensure AI is harnessed safely and effectively to support pharmacists and patients," she adds.

Pharmacies that deliver prescriptions nationwide are set to benefit from new financial support from the Department of Science, Innovation, and Technology funding plan announced earlier this month. In an announcement aimed at improving productivity and public services supported by a share of £32 million, the Department of Science, Innovation and Technology said it is set to make major investments in Artificial Intelligence (AI) technologies, including the mission to "build an NHS which is fit for the future". A Nottingham-based organisation, Anteam, is one of the key beneficiaries of this plan and will be working alongside retailers and the NHS to improve the efficiency of their deliveries using AI algorithms. "This technology will match the delivery needs of retailers and hospitals to existing delivery journeys, unlocking under-utilised capacity, cutting carbon emissions and delivering a better experience for patients," the Department said. Minister of Digital Government and AI, Feryal Clark, emphasised the importance of AI in transforming public services. "AI will deliver real change for working people across the UK - not only growing our economy but improving our public services," she stated.

The Company Chemists' Association (CCA) has voiced strong support for a recent report from the Tony Blair Institute (TBI), which advocates for the establishment of a 'Digital Health Record' (DHR) for every individual in the UK. The CCA, which was interviewed as part of the report's development, believes that the creation of a DHR could significantly enhance the NHS's efficiency, improve preventative healthcare, and help the health service harness the full potential of artificial intelligence (AI). The TBI report highlights that the current health and care system suffers from fragmented data, with individual records scattered across various providers, including community pharmacies. This siloed approach often hampers the delivery of seamless and effective care. A unified DHR, the report argues, would consolidate all relevant health data into a single, accessible record, ensuring that patients receive timely and appropriate care across the entire healthcare system.

In recent years, the healthcare sector has seen a significant transformation driven by the rapid advancement of technology. From improved patient care to streamlined administrative processes, technology has become an indispensable part of modern healthcare. As medical facilities worldwide embrace these innovations, it's essential to understand why the sector leans so heavily on advanced technological solutions. Below are seven key reasons illustrating the crucial role of technology in healthcare. Enhanced Radiology Workflows Advancements in technology have revolutionized radiology workflows, making the process more efficient and accurate. Digital imaging technologies, such as PACS (Picture Archiving and Communication Systems) and RIS (Radiology Information Systems), allow for the seamless storage, retrieval, and sharing of medical images. The specialists AbbaDox say that this reduces the time needed to diagnose and treat patients, significantly improving the overall efficiency of radiology departments. Additionally, AI-powered tools can assist radiologists by highlighting potential areas of concern within images, ensuring that abnormalities are not overlooked. These improvements contribute to faster, more accurate diagnoses and better patient outcomes.

Medical professionals often prescribe semaglutide to patients who have type 2 diabetes. Along with a balanced diet and regular exercise, it has also shown to be an incredibly efficient weight loss aid for patients. As the active ingredient in well-known brand-name drugs such as Wegovy, Ozempic, and Rybelsus, semaglutide is currently on everybody's lips. But what exactly is semaglutide? Does it really work for weight loss? We'll find an answer for you in this article, and explain the main benefits of using semaglutide for weight loss. What Is Semaglutide? A number of diabetic and weight loss medications, including Wegovy, Ozempic, and Rybelsus, have semaglutide as their active ingredient. This substance is a synthetic form of the hormone glucagon-like peptide-1 (GLP-1), that occurs naturally. Developed by the company Novo Nordisk, semaglutide was first approved by the FDA in 2017 as an injection for the treatment of adult type 2 diabetes (as part of the approval procedure for Ozempic). In 2019, the Food and Drug Administration approved a novel semaglutide form known as Rybelsus. Rybelsus was the first oral GLP-1 receptor agonist for the treatment of type 2 diabetes in the United States.

Have you ever wanted to know how vaccines are sent out from a lab to your doctor's office safely? Well, believe it or not, the integrity of the vaccines relies on how they have been packed just as much as how they are being transported. And the entire process is not as simple as you may think. Traditionally, styrofoam boxes might work well to secure glass or delicate goods during transportation but when it comes to hauling vials of liquid vaccine solutions out to medical centres and hospitals; the packing process must be more rigorous-understandably. The integrity of the vaccines, being transported, must adhere to particular protocols from the second they are packed right up to the moment they are administered. This process sounds strict and that's because it is. If vaccines are not well-cared for, even during transit, then they are at risk of being contaminated or damaged therefore rendering them unusable. Incorrectly transporting vaccines, which will end up being destroyed, is something nobody wants to happen therefore vaccine transportation must be strict. One of the best ways to ensure the safe and efficient transit of medical goods, like vaccines, is by using bioprocess containers. These containers are specifically designed to maintain the integrity of sensitive biological materials throughout their journey.

A novel bioinformatics approach can predict vaccine effectiveness for the influenza season, and indicates that the current vaccines are likely to be effective against H3N2 flu viruses in the U.S. 2017/2018 flu season, according to research published online Nov. 29 in F1000 Research. Slobodan Paessler, D.V.M., Ph.D., from the University of Texas Medical Branch, and Veljko Veljkovic, Ph.D., from Biomed Protection, both in Galveston, Texas, used a bioinformatics platform to predict vaccine effectiveness for the 2017/2018 influenza season in the United States. The hemagglutinin HA1 region of 251 and 113 human H3N2 viruses collected in Australia and the United States from July to September 2017 were analyzed. The informational spectrum method-based phylogenetic analysis of H3N2 viruses was performed to serve as a base for predicting vaccine effectiveness. The researchers found that analyses of Australian viruses generated two clusters; the vaccine virus was placed in the smaller group. As a result, the vaccine was predicted not to be efficient against most Australian H3N2 viruses in the 2017 flu season; low vaccine effectiveness was reported in Australia in the 2017 flu season in accordance with this prediction. The U.S. H3N2 viruses were also grouped into two clusters, but the vaccine virus was placed in the largest cluster encompassing 71 percent of analyzed viruses. Consequently, the vaccine effectiveness is expected not to be suboptimal in the United States.